ObsEva SA (OBSV)
After hours:
| Previous close | 1.6700 |
| Open | 1.7600 |
| Bid | 1.6800 x 1400 |
| Ask | 1.7700 x 1400 |
| Day's range | 1.6900 - 1.7750 |
| 52-week range | 1.0800 - 3.5800 |
| Volume | |
| Avg. volume | 502,138 |
| Market cap | 138.01M |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8220 |
| Earnings date | 03 Mar 2022 - 07 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.38 |
- Globe Newswire
ObsEva Announces Corporate Updates
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc.
- Globe Newswire
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th World Congress- GENEVA, Switzerland May 25, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist. These data were featured in
- Globe Newswire
ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company’s Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva’s Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decide
